Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ofatumumab plus fludarabine-cyclophosphamide vs fludarabine-cyclophosphamide in relapsed chronic lymphocytic leukemia
2008-005811-16Phase 3Completed
- Sponsor
- GSK
- Start
- Jan 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ofatumumab in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) (2 arms), sponsored by GSK. Primary endpoint: Progression-free survival. Started Jan 2009; status: completed.
02
Drugs
ofatumumab
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2008-005811-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-005811-16.